CA3127501A1 - Therapeutic agents and methods of treatment - Google Patents
Therapeutic agents and methods of treatment Download PDFInfo
- Publication number
- CA3127501A1 CA3127501A1 CA3127501A CA3127501A CA3127501A1 CA 3127501 A1 CA3127501 A1 CA 3127501A1 CA 3127501 A CA3127501 A CA 3127501A CA 3127501 A CA3127501 A CA 3127501A CA 3127501 A1 CA3127501 A1 CA 3127501A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- independently
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962803299P | 2019-02-08 | 2019-02-08 | |
| US62/803,299 | 2019-02-08 | ||
| PCT/US2020/017364 WO2020163823A2 (en) | 2019-02-08 | 2020-02-07 | Therapeutic agents and methods of treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3127501A1 true CA3127501A1 (en) | 2020-08-13 |
Family
ID=71948254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3127501A Pending CA3127501A1 (en) | 2019-02-08 | 2020-02-07 | Therapeutic agents and methods of treatment |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220169628A1 (https=) |
| EP (1) | EP3920923A4 (https=) |
| JP (1) | JP2022520061A (https=) |
| KR (1) | KR20210137025A (https=) |
| CN (1) | CN113660937A (https=) |
| AU (1) | AU2020218367A1 (https=) |
| CA (1) | CA3127501A1 (https=) |
| WO (1) | WO2020163823A2 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021207672A1 (en) | 2020-01-15 | 2022-07-14 | University Of Florida Research Foundation, Incorporated | Therapeutic agents and methods of treatment |
| WO2022072094A2 (en) * | 2020-08-28 | 2022-04-07 | University Of Florida Research Foundation, Incorporated | Modulators of nuclear receptor subfamily 4 group a member 1 (nr4a1) and uses thereof |
| CN117794929A (zh) | 2021-02-02 | 2024-03-29 | 法国施维雅药厂 | 选择性bcl-xl protac化合物及使用方法 |
| CA3231175A1 (en) | 2021-09-01 | 2023-03-09 | Xizang Haisco Pharmaceutical Co., Ltd. | Compound for degradation of bcl-2 family proteins and medical application thereof |
| US20240398764A1 (en) * | 2021-10-12 | 2024-12-05 | University Of Florida Research Foundation, Incorporated | Methods of treating diseases associated with senescent cell accumulation |
| WO2023107606A1 (en) | 2021-12-09 | 2023-06-15 | University Of Florida Research Foundation, Incorporated | Bcl-xl/bcl-2 dual degraders for treatment of cancers |
| AU2022424178A1 (en) | 2021-12-30 | 2024-07-11 | Beone Medicines I Gmbh | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use |
| EP4461730A4 (en) * | 2022-01-04 | 2025-12-24 | Univ Shanghai Technology | PROTEIN DEGRADING AGENTS DEVELOPED BASED ON BCL-2 FAMILY PROTEIN LIGAND COMPOUNDS AND THEIR USE |
| US20250282771A1 (en) | 2022-05-06 | 2025-09-11 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders |
| PE20250007A1 (es) | 2022-05-06 | 2025-01-07 | Treeline Biosciences Inc | Degradadores bcl-xl-heterobifuncionales de tetrahidroisoquinolina |
| JP2025516359A (ja) | 2022-05-06 | 2025-05-27 | ツリーライン バイオサイエンシズ インコーポレイテッド | テトラヒドロイソキノリンヘテロ二官能性ｂｃｌ－ｘｌ分解剤 |
| CN115028679B (zh) * | 2022-08-11 | 2022-11-15 | 深圳湾实验室 | 一种具有Cyclophilin A降解活性的PROTAC化合物及其制备方法与应用 |
| JP2025533820A (ja) * | 2022-10-03 | 2025-10-09 | ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド | セレブロン動員性Ｂｃｌ－ｘＬ／Ｂｃｌ－２二重分解剤 |
| WO2024078581A1 (en) * | 2022-10-12 | 2024-04-18 | Appicine Therapeutics (Hk) Limited | Selective bcl-xl protac compounds and uses thereof |
| WO2024153185A1 (zh) * | 2023-01-18 | 2024-07-25 | 苏州宜联生物医药有限公司 | 包含bcl-2家族蛋白降解剂的抗体药物偶联物及其制备方法和用途 |
| JP2026507476A (ja) * | 2023-02-17 | 2026-03-04 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | トリフルオロメタンスルホニル基を含む化合物 |
| WO2025101571A1 (en) | 2023-11-07 | 2025-05-15 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-x l degraders |
| WO2025101575A1 (en) | 2023-11-07 | 2025-05-15 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-x l degraders |
| TW202527930A (zh) | 2023-11-07 | 2025-07-16 | 美商樹線生物科學公司 | 四氫異喹啉異雙功能ｂｃｌ－ｘｌ降解劑 |
| WO2026015489A1 (en) * | 2024-07-08 | 2026-01-15 | University Of Florida Research Foundation, Incorporated | Bcl-xl/bcl-2 dual degraders and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7973161B2 (en) * | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| JP6817962B2 (ja) * | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| US10730870B2 (en) * | 2015-03-18 | 2020-08-04 | Arvinas Operations, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| WO2017024317A2 (en) * | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| EP3337476A4 (en) * | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| JP6936498B2 (ja) * | 2016-04-21 | 2021-09-15 | バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーＢｉｏＶｅｎｔｕｒｅｓ， ＬＬＣ | 抗アポトーシス性Ｂｃｌ−２ファミリータンパク質の分解を誘導する化合物及びその使用 |
| EP4491236A3 (en) * | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| JP2020514252A (ja) * | 2016-12-08 | 2020-05-21 | アイカーン スクール オブ メディスン アット マウント シナイ | Ｃｄｋ４／６媒介性がんを治療するための組成物および方法 |
| US20240398764A1 (en) * | 2021-10-12 | 2024-12-05 | University Of Florida Research Foundation, Incorporated | Methods of treating diseases associated with senescent cell accumulation |
| WO2023107606A1 (en) * | 2021-12-09 | 2023-06-15 | University Of Florida Research Foundation, Incorporated | Bcl-xl/bcl-2 dual degraders for treatment of cancers |
-
2020
- 2020-02-07 WO PCT/US2020/017364 patent/WO2020163823A2/en not_active Ceased
- 2020-02-07 CA CA3127501A patent/CA3127501A1/en active Pending
- 2020-02-07 CN CN202080027337.5A patent/CN113660937A/zh active Pending
- 2020-02-07 EP EP20753239.1A patent/EP3920923A4/en not_active Withdrawn
- 2020-02-07 US US17/429,207 patent/US20220169628A1/en active Pending
- 2020-02-07 KR KR1020217028572A patent/KR20210137025A/ko not_active Ceased
- 2020-02-07 JP JP2021546264A patent/JP2022520061A/ja active Pending
- 2020-02-07 AU AU2020218367A patent/AU2020218367A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN113660937A (zh) | 2021-11-16 |
| AU2020218367A1 (en) | 2021-08-12 |
| WO2020163823A8 (en) | 2020-10-01 |
| EP3920923A2 (en) | 2021-12-15 |
| US20220169628A1 (en) | 2022-06-02 |
| WO2020163823A3 (en) | 2020-10-29 |
| JP2022520061A (ja) | 2022-03-28 |
| EP3920923A4 (en) | 2022-10-26 |
| KR20210137025A (ko) | 2021-11-17 |
| WO2020163823A2 (en) | 2020-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3127501A1 (en) | Therapeutic agents and methods of treatment | |
| EP3743069B1 (en) | Bcl-2 proteins degraders for cancer treatment | |
| US12441722B2 (en) | Therapeutic agents and methods of treatment | |
| JP7754865B2 (ja) | Ｔｌｒ７／８アンタゴニストおよびそれらの使用 | |
| AU2017254687A1 (en) | Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof | |
| CA3193577A1 (en) | Compounds and compositions as modulators of tlr signaling | |
| CN116783183B (zh) | 用于治疗贫血和癌症的vhl抑制剂 | |
| JP2024508728A (ja) | Ｎｌｒｐ３阻害剤としての化合物 | |
| AU2021287462A1 (en) | Compounds comprising a three ring core as PD-1/PD-L1 blockers | |
| HK40060209A (en) | Therapeutic agents and methods of treatment | |
| HK40074265A (en) | Therapeutic agents and methods of treatment | |
| CA3018991C (en) | Compounds that induce degradation of anti-apoptotic bcl-2 family proteins and the uses thereof | |
| KR20180134401A (ko) | 예를 들어 알츠하이머병을 치료하기 위한 선택적 BACE1 억제제로서 N-[3-[2-아미노-5-(1,1-디플루오로에틸)-4,4a,5,7-테트라히드로푸로[3,4-d][1,3]옥사진-7a-일]-4-플루오로-페닐]-5-(트리플루오로메틸)피리딘-2-카르복스아미드 및 그의 (4aR,5S,7aS) 이성질체 | |
| HK40038404B (en) | Bcl-2 proteins degraders for cancer treatment | |
| HK40038404A (en) | Bcl-2 proteins degraders for cancer treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220811 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20241028 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250902 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20251103 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260102 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260323 |